According to Fintel reports, on May 26, 2023, Oppenheimer restated its coverage of Harmony Biosciences Holdings (NASDAQ: HRMY) with an Outperform recommendation. The average one-year price target for Harmony Biosciences Holdings as of May 11, 2023, is 61.88, with a projected annual revenue of 591MM, an increase of 25.35%, and a projected annual non-GAAP EPS of 2.76. This represents an increase of 71.94% from its latest reported closing price of 35.99.
As per Fintel’s leaderboard of companies with the largest price target upside, there are 557 funds or institutions reporting positions in Harmony Biosciences Holdings. Valor Management holds the highest percentage of shares at 18.71%, followed by Vivo Capital at 4.35%, and IJR – iShares Core S&P Small-Cap ETF at 3.60%. The put/call ratio of HRMY is 7.42, indicating a bearish outlook.
Adage Capital Partners Gp, L.l.c. holds 1,415K shares representing 2.36% ownership of the company, with an increase of 90.81%. The firm increased its portfolio allocation in HRMY by 504.74% over the last quarter.
Harmony Biosciences Holdings is a pharmaceutical company that focuses on the research, drug development, and treatment for neurologic disorder of sleep-wake state instability. The company primarily serves patients in the United States.
Key filings for this company are available on Fintel’s website. Please note that the views and opinions expressed herein are those of the author and do not necessarily reflect those of Nasdaq, Inc.
